ARTICLE · 07 OCTOBER 2026
Protecting The AI Drug Discovery Ecosystem: Building An IP Stack Around Targets, Molecules And Medicines
As computational biology and artificial intelligence reshape drug discovery, pharmaceutical companies face a critical challenge: how to protect not just the final therapeutic compound, but the entire ecosystem of datasets, models, and biological insights that enabled its creation. This article examines the evolving intellectual property landscape where 90% of clinical candidates still fail, yet the tools predicting their success are becoming as valuable as the medicines themselves.
United KingdomIntellectual Property
Despite the considerable costs and effort in target identification, candidate generation, selection and advancement to clinical trials, 90% of candidates that enter clinical trials during drug discovery fail (Sun D, 2022). The complexity of biological systems remains a major stumbling block in the drug development pipeline. Large datasets such as multiomic datasets and complex analysis methods (for example genome-wide association studies, transcriptomic profiling, proteomic interaction mapping, and metabolic sequencing) have been used to help identify targets with the potential to interact with a given drug and to also identify biological relationships that influence therapeutic activity (Liu Y. Z., 2026) (Pun, 2026) (Rehman AU, 2024). The combination of multiomics with AI, can identify complex relationships across heterogeneous and noisy datasets and can further correlate variables that may be difficult to detect using conventional statistical approaches. This may enable improved
We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
View source